What is Lexeo Therapeutics Inc's earnings per share (EPS)?

Lexeo Therapeutics Inc (LXEO) reported diluted earnings per share of $-1.86 for fiscal year 2026. This represents a 39.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lexeo Therapeutics Inc Financials

LXEO

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Lexeo Therapeutics Inc (LXEO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LXEO FY2025 2026-05-11

Lexeo’s development-stage model is driven by heavy cash burn financed through external capital rather than operating revenue.

Net loss of $100.0M and operating cash outflow of $98.6M were nearly identical, which means losses are mostly cash spending rather than accounting noise. With capital spending only $397K and financing inflow at $216.8M, the stronger balance sheet came from outside capital, not from the operating engine.

The balance sheet is light on obligations: liabilities were just $22.0M and the current ratio was 11.2x, so near-term bills are not the immediate pressure point. The real constraint is runway, because free cash flow was almost -$99.0M while reported revenue was still absent from the latest annual row.

R&D fell by about $10.3M year over year, but SG&A rose to $45.5M, so spending shifted rather than truly eased. That pattern matches an equity-funded buildout: total assets reached $268.7M even as liabilities declined to $22.0M.

Financial Health Signals

Financial Profile 33/100

Based on FY2026 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Lexeo Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Lexeo Therapeutics Inc carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 11.21, Lexeo Therapeutics Inc holds $11.21 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Lexeo Therapeutics Inc generates a -40.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -84.2% the prior year.

Piotroski F-Score Weak

3/9

Lexeo Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.99x

For every $1 of reported earnings, Lexeo Therapeutics Inc generates $0.99 in operating cash flow (-$98.6M OCF vs -$100.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1150.1x

Lexeo Therapeutics Inc earns $-1150.1 in operating income for every $1 of interest expense (-$109.3M vs $95K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$109.0M

YoY-3.3%

Lexeo Therapeutics Inc's EBITDA was -$109.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.3% from the prior year.

Net Income

-$100.0M

YoY-1.7%

Lexeo Therapeutics Inc reported -$100.0M in net income in fiscal year 2026. This represents a decrease of 1.7% from the prior year.

EPS (Diluted)

$-1.86

YoY+39.8%

Lexeo Therapeutics Inc earned $-1.86 per diluted share (EPS) in fiscal year 2026. This represents an increase of 39.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$99.0M

YoY-21.2%

Lexeo Therapeutics Inc generated -$99.0M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 21.2% from the prior year.

Cash & Debt

$63.0M

YoY+79.9%

Lexeo Therapeutics Inc held $63.0M in cash against $0 in long-term debt as of fiscal year 2026.

Dividends Per Share

N/A

Shares Outstanding

73M

YoY+120.7%

Lexeo Therapeutics Inc had 73M shares outstanding in fiscal year 2026. This represents an increase of 120.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-40.5%

YoY+43.6pp

Lexeo Therapeutics Inc's ROE was -40.5% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 43.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$63.8M

YoY-13.9%

Lexeo Therapeutics Inc invested $63.8M in research and development in fiscal year 2026. This represents a decrease of 13.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$397K

YoY-17.5%

Lexeo Therapeutics Inc invested $397K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 17.5% from the prior year.

LXEO Income Statement

Metric	FY26	FY24	FY23	FY22
Revenue	N/A	N/A	N/A	$654K
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$63.8M-13.9%	$74.1M+39.5%	$53.1M+8.1%	$49.2M
SG&A Expenses	$45.5M+43.5%	$31.7M+105.9%	$15.4M+28.2%	$12.0M
Operating Income	-$109.3M-3.3%	-$105.8M-54.4%	-$68.5M-13.2%	-$60.5M
Interest Expense	$95K-30.7%	$137K-33.2%	$205K+125.3%	$91K
Income Tax	$0	$0	N/A	N/A
Net Income	-$100.0M-1.7%	-$98.3M-48.1%	-$66.4M-12.0%	-$59.3M
EPS (Diluted)	$-1.86+39.8%	$-3.09+75.1%	$-12.40	$-36.36

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$15.7M	N/A	$15.7M+6.6%	$14.7M-14.3%	$17.2M	N/A	$23.4M+41.4%	$16.6M
SG&A Expenses	$6.6M	N/A	$6.0M-62.7%	$16.0M-4.0%	$16.6M	N/A	$8.1M+16.2%	$7.0M
Operating Income	-$22.3M	N/A	-$21.6M+29.5%	-$30.7M+9.2%	-$33.8M	N/A	-$31.5M-33.9%	-$23.6M
Interest Expense	$17K	N/A	$22K-12.0%	$25K-10.7%	$28K	N/A	$35K0.0%	$35K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$20.2M	N/A	-$20.3M+22.3%	-$26.1M+20.1%	-$32.7M	N/A	-$29.5M-38.9%	-$21.2M
EPS (Diluted)	$-0.25	N/A	$-0.33+45.0%	$-0.60+39.4%	$-0.99	N/A	$-0.89-39.1%	$-0.64

LXEO Balance Sheet

Metric	FY26	FY24	FY23	FY22
Total Assets	$268.7M+82.9%	$146.9M+5.1%	$139.8M+44.0%	$97.1M
Current Assets	$188.4M+49.4%	$126.1M+1.5%	$124.3M+55.3%	$80.0M
Cash & Equivalents	$63.0M+79.9%	$35.0M-71.2%	$121.5M+57.1%	$77.3M
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$22.0M-26.8%	$30.1M+14.6%	$26.3M-87.5%	$210.0M
Current Liabilities	$16.8M-26.4%	$22.8M+32.5%	$17.2M+20.1%	$14.3M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$246.7M+111.1%	$116.8M+2.9%	$113.5M+200.5%	-$113.0M
Retained Earnings	-$380.1M-35.7%	-$280.2M-54.1%	-$181.8M-57.5%	-$115.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$250.4M-6.8%	$268.7M+86.8%	$143.8M-18.3%	$176.1M+40.1%	$125.7M-14.5%	$146.9M-15.5%	$173.9M-9.4%	$192.0M
Current Assets	$200.9M+6.6%	$188.4M+47.4%	$127.8M-8.8%	$140.1M+33.0%	$105.3M-16.5%	$126.1M-20.9%	$159.5M-10.0%	$177.1M
Cash & Equivalents	$71.8M+13.9%	$63.0M+53.7%	$41.0M+15.5%	$35.5M+22.7%	$28.9M-17.4%	$35.0M-77.7%	$157.0M-10.3%	$175.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$18.9M-14.4%	$22.0M-4.3%	$23.0M-39.2%	$37.9M+0.7%	$37.6M+24.8%	$30.1M-12.9%	$34.5M+27.6%	$27.1M
Current Liabilities	$14.2M-15.6%	$16.8M-2.7%	$17.3M-45.3%	$31.6M+2.5%	$30.8M+34.9%	$22.8M-14.8%	$26.8M+42.1%	$18.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$231.5M-6.2%	$246.7M+104.1%	$120.8M-12.6%	$138.2M+56.9%	$88.1M-24.6%	$116.8M-16.1%	$139.3M-15.5%	$164.9M
Retained Earnings	-$400.3M-5.3%	-$380.1M-5.8%	-$359.2M-6.0%	-$338.9M-8.3%	-$312.8M-11.7%	-$280.2M-10.2%	-$254.2M-13.1%	-$224.8M

LXEO Cash Flow Statement

Metric	FY26	FY24	FY23	FY22
Operating Cash Flow	-$98.6M-21.5%	-$81.2M-36.4%	-$59.5M-9.0%	-$54.6M
Capital Expenditures	$397K-17.5%	$481K+318.3%	$115K-82.9%	$672K
Free Cash Flow	-$99.0M-21.2%	-$81.6M-36.9%	-$59.6M-7.9%	-$55.2M
Investing Cash Flow	-$90.3M+4.1%	-$94.1M-56916.4%	-$165K+81.7%	-$901K
Financing Cash Flow	$216.8M+144.2%	$88.8M-14.5%	$103.8M+54815.9%	$189K
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$21.1M-5.3%	-$20.1M+32.0%	-$29.5M-8.6%	-$27.2M-25.3%	-$21.7M+23.3%	-$28.3M-59.1%	-$17.8M+11.6%	-$20.2M
Capital Expenditures	$35K	$0-100.0%	$289K	N/A	N/A	$0-100.0%	$83K-61.0%	$213K
Free Cash Flow	-$21.2M-5.5%	-$20.1M+32.7%	-$29.8M	N/A	N/A	-$28.3M-58.3%	-$17.9M+12.2%	-$20.4M
Investing Cash Flow	$27.5M+127.0%	-$101.7M-390.4%	$35.0M+189.4%	-$39.2M-351.1%	$15.6M+116.7%	-$93.6M-112650.6%	-$83K+61.9%	-$218K
Financing Cash Flow	$2.5M-98.3%	$143.8M+276384.6%	$52K-99.9%	$73.0M+663172.7%	$11K+111.3%	-$97K-34.7%	-$72K-124.7%	$291K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LXEO Financial Ratios

Metric	FY26	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-9252.1%
Net Margin	N/A	N/A	N/A	-9063.8%
Return on Equity	-40.5%+43.6pp	-84.2%-25.7pp	-58.5%	N/A
Return on Assets	-37.2%+29.7pp	-66.9%-19.4pp	-47.5%+13.6pp	-61.1%
Current Ratio	11.21+5.7	5.52-1.7	7.21+1.6	5.58
Debt-to-Equity	0.09-0.2	0.26+0.0	0.23+2.1	-1.86
FCF Margin	N/A	N/A	N/A	-8445.3%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-8.7%	N/A	-16.8%+2.1pp	-18.9%+18.2pp	-37.1%	N/A	-21.2%-8.3pp	-12.9%
Return on Assets	-8.1%	N/A	-14.1%+0.7pp	-14.8%+11.1pp	-26.0%	N/A	-17.0%-5.9pp	-11.1%
Current Ratio	14.16+2.9	11.21+3.8	7.40+3.0	4.43+1.0	3.42-2.1	5.52-0.4	5.95-3.4	9.38
Debt-to-Equity	0.080.0	0.09-0.1	0.19-0.1	0.27-0.2	0.43+0.2	0.260.0	0.25+0.1	0.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Monopar Therapeutics Inc MNPR

$422.8M

Omeros OMER

$829.4M

Capricor Therapeutics Inc CAPR

$1.7B

Alector ALEC

$245.4M

Mereo Biopharma MREO

$44.4M

Frequently Asked Questions

Is Lexeo Therapeutics Inc profitable?

No, Lexeo Therapeutics Inc (LXEO) reported a net income of -$100.0M in fiscal year 2026.

What is Lexeo Therapeutics Inc's EBITDA?

Lexeo Therapeutics Inc (LXEO) had EBITDA of -$109.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Lexeo Therapeutics Inc's return on equity (ROE)?

Lexeo Therapeutics Inc (LXEO) has a return on equity of -40.5% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Lexeo Therapeutics Inc's free cash flow?

Lexeo Therapeutics Inc (LXEO) generated -$99.0M in free cash flow during fiscal year 2026. This represents a -21.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lexeo Therapeutics Inc's operating cash flow?

Lexeo Therapeutics Inc (LXEO) generated -$98.6M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Lexeo Therapeutics Inc's total assets?

Lexeo Therapeutics Inc (LXEO) had $268.7M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Lexeo Therapeutics Inc's capital expenditures?

Lexeo Therapeutics Inc (LXEO) invested $397K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Lexeo Therapeutics Inc spend on research and development?

Lexeo Therapeutics Inc (LXEO) invested $63.8M in research and development during fiscal year 2026.

How many shares does Lexeo Therapeutics Inc have outstanding?

Lexeo Therapeutics Inc (LXEO) had 73M shares outstanding as of fiscal year 2026.

What is Lexeo Therapeutics Inc's current ratio?

Lexeo Therapeutics Inc (LXEO) had a current ratio of 11.21 as of fiscal year 2026, which is generally considered healthy.

What is Lexeo Therapeutics Inc's debt-to-equity ratio?

Lexeo Therapeutics Inc (LXEO) had a debt-to-equity ratio of 0.09 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lexeo Therapeutics Inc's return on assets (ROA)?

Lexeo Therapeutics Inc (LXEO) had a return on assets of -37.2% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Lexeo Therapeutics Inc's cash runway?

Based on fiscal year 2026 data, Lexeo Therapeutics Inc (LXEO) had $63.0M in cash against an annual operating cash burn of $98.6M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Lexeo Therapeutics Inc's Piotroski F-Score?

Lexeo Therapeutics Inc (LXEO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lexeo Therapeutics Inc's earnings high quality?

Lexeo Therapeutics Inc (LXEO) has an earnings quality ratio of 0.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Lexeo Therapeutics Inc cover its interest payments?

Lexeo Therapeutics Inc (LXEO) has an interest coverage ratio of -1150.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Lexeo Therapeutics Inc?

Lexeo Therapeutics Inc (LXEO) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.